Pulmonary Inflammation – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pulmonary Inflammation – Drugs In Development, 2024 report and make more profitable business decisions.
Pulmonary Inflammation also called Pnemonia is an infection that inflames air sacs in one or both lungs, which may fill with fluid. Lung inflammation is favored by the combined action of oxidative stress, ACPA and Th17 cells. Widespread of pulmonary inflammation causes increased permeability of the alveolar capillary membrane leading to flooding and collapse of alveoli and severely impaired gas exchange. Pulmonary inflammation varies according to the type of initiating agent and the route of entry, distribution, and persistence.
The Pulmonary Inflammation drugs in development market research report provide comprehensive information on the therapeutics under development for Pulmonary Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Inflammation and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pulmonary Inflammation | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pulmonary Inflammation therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pulmonary Inflammation pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pulmonary Inflammation treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
13therapeutics IncAdiso Therapeutics Inc
Alcea Therapeutics Inc
Applied Therapeutics Inc
Arrowhead Pharmaceuticals Inc
BioCurity Pharmaceuticals Inc
Celularity Inc
Eldec Pharmaceuticals Inc
Epitracker Inc
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Hunan Sanqing Pharmaceutical Co Ltd
ILiAD Biotechnologies LLC
King Saud University
National Cancer Institute US
NemaGen Discoveries Inc
Oxcia AB
Pasteur Institute
Praesidia Biotherapeutics Inc
Shulov Innovative Science Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pulmonary Inflammation reports